{"id":497101,"date":"2020-07-20T13:18:01","date_gmt":"2020-07-20T13:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=497101"},"modified":"2020-07-20T13:18:01","modified_gmt":"2020-07-20T13:18:01","slug":"programmed-deathligand-1-pdl1-nonsmall-cell-lung-cancer-nsclc-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/programmed-deathligand-1-pdl1-nonsmall-cell-lung-cancer-nsclc-market-size-share-trends-epidemiology-forecast-till-2030_497101.html","title":{"rendered":"Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market, Size, Share, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market, Size, Share, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast &#8211; 2030\u2019 report delivers an in-depth understanding of the PD-L1 NSCLC ,historical and forecasted epidemiology as well as the PD-L1 NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">PD-L1 NSCLC market report provides current treatment practices, emerging drugs, PD-L1 NSCLC market share of the individual therapies, current and forecasted PD-L1 NSCLC market size from 2017 to 2030 segmented by seven major markets. The Report also covers current PD-L1 NSCLC treatment practices\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.<\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\" data-mce-mark=\"1\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market\" target=\"_blank\">Key Highlights from&nbsp;PD-L1 NSCLC market report<\/a>:-<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li>Programmed death-ligand 1 (PD-L1) mutated NSCLC total cases in 7MM in 2017 was&nbsp;<strong>242,014 <\/strong><\/li>\n<li>Programmed death-ligand 1 (PD-L1) NSCLC cases in the United States was&nbsp;<strong>89,597&nbsp;<\/strong>in 2017.&nbsp;<\/li>\n<li>Programmed death-ligand 1 (PD-L1) NSCLC cases in Spain in 2017 was&nbsp;<strong>11,585.&nbsp;<\/strong><\/li>\n<li>The total cases of Programmed death-ligand 1 (PD-L1) mutated NSCLC in EU5 countries in 2017 were<\/li>\n<ul>\n<li>Germany &#8211; <strong>28,509 cases<\/strong><\/li>\n<li>France &#8211; <strong>20,110 cases<\/strong><\/li>\n<li>Italy &#8211; <strong>17,021 cases&nbsp;<\/strong><\/li>\n<li>Spain &#8211; <strong>11,585 cases&nbsp;<\/strong><\/li>\n<li>The United Kingdom &#8211;<strong>22,192 cases<\/strong><\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market\" target=\"_blank\"><strong><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">Request for sample pages<\/span><\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">Scope of the Report<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">&bull;&nbsp;The report covers the descriptive overview of PD-L1 NSCLC, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.<\/p>\n<p style=\"text-align: justify;\">&bull; Comprehensive insight has been provided into thePD-L1 NSCLC epidemiology and treatment in the 7MM.<\/p>\n<p style=\"text-align: justify;\">&bull; Additionally, an all-inclusive account of both the current and emerging therapies for PD-L1 NSCLC is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.<\/p>\n<p style=\"text-align: justify;\">&bull; A detailed review of PD-L1 NSCLC market; historical and forecasted is included in the report, covering drug outreach in the 7MM.<\/p>\n<p style=\"text-align: justify;\">&bull; The report provides an edge while developing business strategies, by understanding trends shaping and driving the global PD-L1 NSCLC market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market\" target=\"_blank\">Request for sample pages<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market\" target=\"_blank\"><strong>Programmed death-ligand 1 (PD-L1) mutated NSCLC market size<\/strong> <\/a><strong>in 7MM was<\/strong>&nbsp;<strong>USD 6,536 million&nbsp;in 2017.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-L1 NSCLC Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Increasing Use of Biomarker Testing <\/strong><\/li>\n<li><strong>Increase in the Mutation Specific Trials Activity<\/strong><\/li>\n<li><strong>Increasing Incidence of Programmed death-ligand 1 (PD-L1)&nbsp; mutated NSCLC<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-L1 NSCLC Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Cost-Effectiveness of Therapies<\/strong><\/li>\n<li><strong>Cost of Therapies<\/strong><\/li>\n<li><strong>Burden of Disease<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-L1 NSCLC Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\">PD-1\/PD-L1 blocking antibodies therapy is recommended for the patients showing PD-L1 expressions. In recent years, immunotherapy has revolutionized and changed the standard of care in patients with NSCLC. Immune checkpoint inhibitors, fundamentally those that act by blocking PD-1 and its ligand, the PD-L1, have emerged as novel treatment strategies in NSCLC, demonstrating undoubted superiority over chemotherapy in terms of efficacy.<\/p>\n<p style=\"text-align: justify;\">Several of these immune checkpoint modulators have recently gained regulatory approval for the treatment of advanced NSCLC, such as <strong>Opdivo<\/strong> (nivolumab), <strong>Tecentriq<\/strong> (atezolizumab), <strong>Keytruda<\/strong> (pembrolizumab, and recently, <strong>Imfinzi<\/strong> (durvalumab). Among all of the approved PD-1\/PD-L1 inhibitors, the NSCLC therapy area is dominated by <strong>Keytruda<\/strong> (pembrolizumab), with revenues from this particular market helping the drug to achieve a hit status.<\/p>\n<p style=\"text-align: justify;\"><strong><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">Table of contents<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\"><span>1. Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Executive Summary of PD-L1 NSCLC<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. SWOT Analysis of PD-L1 NSCLC<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. PD-L1 NSCLC Market Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. Total Market Share (%) Distribution of PD-L1 NSCLC in 2017: By Country<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2. Total Market Share (%) Distribution of PD-L1 NSCLC in 2030: By Country<\/p>\n<p style=\"text-align: justify;\"><span>5. PD-L1 Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.1.1. Cellular Classification of NSCLC<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.1.2. Signs and Symptoms of NSCLC<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.1.3. Risk Factors of Lung Cancer<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.1.4. Causes of NSCLC<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.1.5. Disease Biology: NSCLC<\/p>\n<p style=\"text-align: justify;\"><span>6. Diagnosis of PD-L1 NSCLC<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.1. Diagnostic Algorithm for NSCLC<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.2. Stages of NSCLC<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.3. Staging System<\/p>\n<p style=\"text-align: justify;\"><span>7. Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1. Epidemiology Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.1. Total Incident cases of NSCLC patients in the 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.4. The United States Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.1. Total Incident cases of NSCLC patients in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.2. Total Incident cases of NSCLC patients by Histology in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.4. Total PD-L1 NSCLC cases in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.5. Total PD-L1 NSCLC Treated patient Pool in the United States<\/p>\n<p style=\"text-align: justify;\"><span>8. EU-5 Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.1. Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.1. Total Incident cases of NSCLC patients in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.2. Total Incident cases of NSCLC patients by Histology in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.4. Total PD-L1 NSCLC cases in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.5. Total PD-L1 NSCLC Treated patient Pool in Germany<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.2. France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.1. Total Incident cases of NSCLC patients in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.2. Total Incident cases of NSCLC patients by Histology in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.4. Total PD-L1 NSCLC cases in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.5. Total PD-L1 NSCLC Treated patient Pool in France<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.3. Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.1. Total Incident cases of NSCLC patients in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.2. Total Incident cases of NSCLC patients by Histology in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.4. Total PD-L1 NSCLC cases in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.5. Total PD-L1 NSCLC Treated patient Pool in Italy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.4. Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.4.1. Total Incident cases of NSCLC patients in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.4.2. Total Incident cases of NSCLC patients by Histology in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.4.4. Total PD-L1 NSCLC cases in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.4.5. Total PD-L1 NSCLC Treated patient Pool in Spain<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.5. The United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.5.1. Total Incident cases of NSCLC patients in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.5.4. Total PD-L1 NSCLC cases in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.5.5. Total PD-L1 NSCLC Treated patient Pool in the United Kingdom<\/p>\n<p style=\"text-align: justify;\"><span>9. Japan Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">9.1. Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">9.1.1. Total Incident cases of NSCLC patients in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">9.1.2. Total Incident cases of NSCLC patients by Histology in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">9.1.4. Total PD-L1 NSCLC cases in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">9.1.5. Total PD-L1 NSCLC Treated patient Pool in Japan<\/p>\n<p style=\"text-align: justify;\"><span>10. Current Treatment Practices: PD-L1 NSCLC<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.1. Advanced\/Metastatic NSCLC Treatment Algorithm<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.2. Chemotherapy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.3. Targeted Therapy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.4. Immunotherapy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.5. Surgery<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.6. Radiation Therapy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.7. Stage-wise Treatment Options of NSCLC<\/p>\n<p style=\"text-align: justify;\"><span>11. Guideline of NSCLC<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018<\/p>\n<p style=\"text-align: justify;\"><span>12. Unmet Needs of PD-L1 NSCLC<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13. Key Endpoints in NSCLC Clinical Trials<\/span><\/p>\n<p style=\"text-align: justify;\"><span>14. PD-L1 NSCLC<strong>&nbsp;<\/strong>Marketed Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.1. Key Cross<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.2. Imfinzi (Durvalumab): AstraZeneca<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.4. Pivotal Clinical Trials<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.5. Ongoing Current Pipeline Activity<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.6. Safety and Efficacy of Ongoing Clinical Trials<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.3. Opdivo (Nivolumab): Bristol-Myers Squibb<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.4. Pivotal Clinical Trials<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.5. Ongoing Current Pipeline Activity<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.4. Tecentriq (Atezolizumab): Genentech\/Hoffmann-La Roche<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.4. Pivotal Clinical Trials<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.5. Ongoing Current Pipeline Activity<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.5. Keytruda (Pembrolizumab): Merck<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.5.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.5.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.5.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.5.4. Pivotal Clinical Trials<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.5.5. Ongoing Current Pipeline Activity<\/p>\n<p style=\"text-align: justify;\"><span>15. Emerging Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1. Canakinumab (ACZ885): Novartis Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.2. Clinical Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2. Avelumab (Bavencio): Merck KGaA and Pfizer<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.2.2. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.2.3. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.3. Libtayo (Cemiplimab): Regeneron Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.2. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.3. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.4. M7824 (Bintrafusp alfa): GlaxoSmithKline\/Merck KGaA<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.2. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><span>16. PD-L1Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.2. Market Outlook: 7MM<\/p>\n<p style=\"text-align: justify;\"><span>17. PD-L1&mdash;Market Size<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.1. Total Market Size of PD-L1 NSCLC in the 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.2. Market Size of PD-L1 NSCLC by Therapeutic Class in the 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.3. United States Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">17.3.1. Total Market size of PD-L1 NSCLC in the United States<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.4. EU-5 Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">17.4.1. Germany Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">17.4.2. France Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">17.4.3. Italy Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">17.4.4. Spain Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">17.4.5. United Kingdom Market Size<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.5. Japan Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">17.5.1. Total Market size of PD-L1 NSCLC in Japan<\/p>\n<p style=\"text-align: justify;\"><span>18. Market Access and Reimbursement of PD-L1 NSCLC Therapies<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19. PD-L1 NSCLC Market Drivers&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. PD-L1 NSCLC Market Barriers&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21. Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">21.1. Bibliography<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">21.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><span>22. DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>23. Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>24. About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> DelveInsight<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=programmed-deathligand-1-pdl1-nonsmall-cell-lung-cancer-nsclc-market-size-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=programmed-deathligand-1-pdl1-nonsmall-cell-lung-cancer-nsclc-market-size-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight DelveInsight\u2019s \u2018Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast &#8211; 2030\u2019 report delivers an in-depth understanding of the PD-L1 NSCLC ,historical and forecasted epidemiology as well as the PD-L1 NSCLC market trends &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/programmed-deathligand-1-pdl1-nonsmall-cell-lung-cancer-nsclc-market-size-share-trends-epidemiology-forecast-till-2030_497101.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-497101","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=497101"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497101\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=497101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=497101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=497101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}